Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Paola Lichtenberger is active.

Publication


Featured researches published by Paola Lichtenberger.


Nature | 2017

Genomic epidemiology reveals multiple introductions of Zika virus into the United States

Nathan D. Grubaugh; Jason T. Ladner; Moritz U. G. Kraemer; Gytis Dudas; Amanda L. Tan; Karthik Gangavarapu; Michael R. Wiley; Stephen White; Julien Thézé; Diogo M. Magnani; Karla Prieto; Daniel Reyes; Andrea M. Bingham; Lauren M. Paul; Refugio Robles-Sikisaka; Glenn Oliveira; Darryl Pronty; Carolyn M. Barcellona; Hayden C. Metsky; Mary Lynn Baniecki; Kayla G. Barnes; Bridget Chak; Catherine A. Freije; Adrianne Gladden-Young; Andreas Gnirke; Cynthia Y. Luo; Bronwyn MacInnis; Christian B. Matranga; Daniel J. Park; James Qu

Zika virus (ZIKV) is causing an unprecedented epidemic linked to severe congenital abnormalities. In July 2016, mosquito-borne ZIKV transmission was reported in the continental United States; since then, hundreds of locally acquired infections have been reported in Florida. To gain insights into the timing, source, and likely route(s) of ZIKV introduction, we tracked the virus from its first detection in Florida by sequencing ZIKV genomes from infected patients and Aedes aegypti mosquitoes. We show that at least 4 introductions, but potentially as many as 40, contributed to the outbreak in Florida and that local transmission is likely to have started in the spring of 2016—several months before its initial detection. By analysing surveillance and genetic data, we show that ZIKV moved among transmission zones in Miami. Our analyses show that most introductions were linked to the Caribbean, a finding corroborated by the high incidence rates and traffic volumes from the region into the Miami area. Our study provides an understanding of how ZIKV initiates transmission in new regions.


Clinical Infectious Diseases | 2017

Multicenter Evaluation of Ceftolozane/Tazobactam for Serious Infections Caused by Carbapenem-Resistant Pseudomonas aeruginosa

Jose M. Munita; Samuel L. Aitken; William Miller; Federico Perez; Rossana Rosa; Luis Shimose; Paola Lichtenberger; Lilian M. Abbo; Rupali Jain; Masayuki Nigo; Audrey Wanger; Rafael Araos; Truc T. Tran; Javier A. Adachi; Robert M. Rakita; Samuel A. Shelburne; Robert A. Bonomo; Cesar A. Arias

A multicenter, retrospective study of patients infected with carbapenem-resistant Pseudomonas aeruginosa who were treated with ceftolozane/tazobactam was performed. Among 35 patients, pneumonia was the most common indication and treatment was successful in 26 (74%). Treatment failure was observed in all cases where isolates demonstrated ceftolozane-tazobactam minimum inhibitory concentrations ≥8 μg/mL.


International Journal of Antimicrobial Agents | 2011

Antimicrobial prophylaxis in women with recurrent urinary tract infections.

Paola Lichtenberger; Thomas M. Hooton

Recurrent urinary tract infections (UTIs) in women are common, result in considerable morbidity and expense, and can be a management problem for clinicians. Behavioural changes can be useful antimicrobial-sparing measures in the prevention of recurrent UTIs, but antimicrobial prophylaxis may be necessary in those who continue to have recurrences. Continuous prophylaxis, post-coital prophylaxis and intermittent self-treatment with antimicrobials have all been demonstrated to be effective in the prevention of recurrent uncomplicated UTIs. The decision as to which approach to use depends upon the frequency and pattern of recurrences and willingness of the patient to commit to a specific regimen. The risk of adverse events, including antimicrobial resistance, patients lifestyle and compliance and plans for a pregnancy also need to be considered. The choice of antimicrobial should be based upon the susceptibility pattern of the organisms causing the patients previous UTIs and history of drug allergies.


Transplant Infectious Disease | 2009

Hyperinfection strongyloidiasis in a liver transplant recipient treated with parenteral ivermectin

Paola Lichtenberger; I. Rosa-Cunha; M. Morris; Seigo Nishida; Edip Akpinar; J. Gaitan; Andreas G. Tzakis; Susanne Doblecki-Lewis

Abstract: Severe strongyloidiasis, including hyperinfection and dissemination, is a recognized complication of solid organ transplantation. However, the development of strongyloidiasis in a liver transplant recipient has not been previously described. We present a case of severe strongyloidiasis occurring in a patient 4 months after liver transplantation and 1 month after receiving treatment for acute rejection. We assess the management challenges in this patient who remained symptomatic despite oral treatment with ivermectin and albendazole and eventual successful treatment with parenteral ivermectin. We review the published experience with alternative methods of ivermectin administration. We also investigate the possible source of infection, as the patient was not from an endemic area.


Infection Control and Hospital Epidemiology | 2010

Infection control in field hospitals after a natural disaster: lessons learned after the 2010 earthquake in Haiti.

Paola Lichtenberger; Ian N. Miskin; Gordon M. Dickinson; Mitchell J. Schwaber; Omer E. Ankol; Marcus J. Zervos; Rafael Campo; Susanne Doblecki-Lewis; MarkAlain Dery; L. Silvia Munoz-Price

After the January 12, 2010, earthquake in Haiti, Project Medishare and the University of Miami organized, built, and staffed a 200-bed field hospital (the University of Miami Hospital in Haiti [UMHH]) on the outskirts of Port-au-Prince. We describe the operational challenges of providing a safe environment at the UMHH. Furthermore, we compared how these issues were addressed at this ad hoc hospital with how they were addressed at the field hospital of the Israel Defense Force, a fully deployable hospital with an organization fine-tuned as a result of prior disaster situations, also in Haiti.


Arthritis & Rheumatism | 2018

Chikungunya Arthritis Mechanisms in the Americas: A Cross-Sectional Analysis of Chikungunya Arthritis Patients Twenty-Two Months After Infection Demonstrating No Detectable Viral Persistence in Synovial Fluid.

Aileen Y. Chang; Karen Martins; Liliana Encinales; St. Patrick Reid; Marlon Acuña; Carlos Encinales; Christian B. Matranga; Nelly Pacheco; Carlos Cure; Bhavarth Shukla; Teofilo Ruiz Arteta; Richard L. Amdur; Lisa H. Cazares; Melissa Gregory; Michael D. Ward; Alexandra Porras; Alejandro Rico Mendoza; Lian Dong; Tara Kenny; Ernie Brueggemann; Lydia G. Downey; Priyanka Kamalapathy; Paola Lichtenberger; Orlando Falls; Gary L. Simon; Jeffrey M. Bethony; Gary S. Firestein

To determine if chikungunya virus persists in synovial fluid after infection, potentially acting as a causative mechanism of persistent arthritis.


Current Infectious Disease Reports | 2008

Complicated urinary tract infections

Paola Lichtenberger; Thomas M. Hooton


BMC Medical Education | 2016

Knowledge, attitudes, and practices of Florida physicians regarding dengue before and after an educational intervention.

Susanne Doblecki-Lewis; Aileen Chang; Renee Jiddou-Yaldoo; Kay M. Tomashek; Danielle Stanek; Leena Anil; Paola Lichtenberger


Implementation Science | 2018

Protocol to disseminate a hospital-site controlled intervention using audit and feedback to implement guidelines concerning inappropriate treatment of asymptomatic bacteriuria

Pooja Prasad; Larissa Grigoryan; Sylvia J. Hysong; Jennifer R. Kramer; Suja S. Rajan; Nancy J. Petersen; Tracey Rosen; Dimitri M. Drekonja; Christopher J. Graber; Payal K. Patel; Paola Lichtenberger; Timothy P. Gauthier; Steve Wiseman; Makoto Jones; Anne Sales; Sarah L. Krein; Aanand D. Naik


Clinical Infectious Diseases | 2018

A PrEP Model Incorporating Clinical Pharmacist Encounters and Antimicrobial Stewardship Program Oversight May Improve Retention in Care

Timothy P. Gauthier; Maribel Toro; Mara Carrasquillo; Mark Corentin; Paola Lichtenberger

Collaboration


Dive into the Paola Lichtenberger's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Aileen Y. Chang

George Washington University

View shared research outputs
Top Co-Authors

Avatar

Audrey Wanger

University of Texas at Austin

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Federico Perez

Case Western Reserve University

View shared research outputs
Top Co-Authors

Avatar

Gary L. Simon

George Washington University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge